MicroRNAs in Diffuse Large B-Cell Lymphoma (DLBCL): Biomarkers with Prognostic Potential
by
, , , ,
Yuliya A. Veryaskina
1,2,*
,
Sergei E. Titov
1,3,
Igor B. Kovynev
4,
Sofya S. Fyodorova
4,
Olga V. Berezina
4,
Igor P. Zhurakovskij
4,
Oksana V. Antonenko
1,
Sergei A. Demakov
1,
Pavel S. Demenkov
5,
Pavel S. Ruzankin
6,7
,
Anton S. Tarasenko
6,7,
Tatiana I. Pospelova
4 and
Igor F. Zhimulev
1 1
Laboratory of Molecular Genetics, Department of the Structure and Function of Chromosomes, Institute of Molecular and Cellular Biology, SB RAS, Novosibirsk 630090, Russia
2
Laboratory of Gene Engineering, Institute of Cytology and Genetics, SB RAS, Novosibirsk 630090, Russia
3
AO Vector-Best, Novosibirsk 630117, Russia
4
Department of Therapy, Hematology and Transfusiology, Novosibirsk State Medical University, Novosibirsk 630091, Russia
5
Laboratory of Computer Proteomics, Institute of Cytology and Genetics, SB RAS, Novosibirsk 630090, Russia
6
Department of Probability Theory and Mathematical Statistics, Novosibirsk State University, Novosibirsk 630090, Russia
7
Sobolev Institute of Mathematics, Novosibirsk 630090, Russia
*
Author to whom correspondence should be addressed.
Cancers 2025, 17(8), 1300; https://doi.org/10.3390/cancers17081300
Submission received: 4 March 2025
/
Revised: 31 March 2025
/
Accepted: 9 April 2025
/
Published: 12 April 2025
(This article belongs to the Special Issue New Insights of Hematology in Cancer)
Simple Summary
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease from both genetic and clinical points of view. Thus, new biomarkers for the diagnosis and prognosis of DLBCL, as well as deciphering the mechanism of action of deregulated microRNAs in the origin of the disease, are needed. From a practical point of view, the results obtained in this study may contribute to the development of personalized therapy. From a fundamental point of view, the obtained data will contribute to the understanding of the pathogenesis of DLBCL.
Abstract
Background/Objectives: The heterogeneity of diffuse large B-cell lymphoma (DLBCL) based on differences in both genetic and epigenetic factors contributes to the dynamics of tumor growth and efficacy of cytoreductive therapy, as well as considerably affecting disease prognosis. This study aimed to detect microRNAs (miRNAs) capable of improving prognostic accuracy in DLBCL patients. Methods: We performed miRNA sequencing in bone marrow (BM) samples collected from DLBCL patients. Next, the expression levels of miRNAs in lymph node (LN) samples (n = 43) and BM samples (n = 70) were analyzed by real-time RT-PCR in the group of DLBCL patients. Results: It was found that the expression levels of miRNA-10b, -100, -125a, -125b, -126, -143, -23a and let-7a were statistically significantly reduced in the group of DLBCL patients who had a poor prognosis compared to DLBCL patients with a favorable prognosis (p < 0.05). Kaplan–Meier survival analysis demonstrated that the upregulated expression of miRNA-23a, miRNA-125a, and miRNA-100 was associated with better overall survival in DLBCL patients. A statistically significant elevation in the expression levels of miRNA-151a, miRNA-148b and miRNA-192 in the BM samples was observed for DLBCL patients both with and without BM involvement compared to BM samples from non-cancerous blood disease (NCBD) patients (p < 0.05). Statistically significant upregulation of PD-L1, TIMP1, TOP2A, and TP53 was observed in BM samples from DLBCL patients with and without BM involvement in comparison with BM samples from NCBD patients (p < 0.05). Conclusions: miRNA-23a, miRNA-125a, and miRNA-100 were shown to be potential prognostically significant biomarkers in DLBCL patients. Changes in expression levels of miRNA-151a, miRNA-148b, miRNA-192, PD-L1, TIMP1, TOP2A, and TP53 reflect alterations in the BM without morphological or immunophenotypic signs of a DLBCL-related BM pathology.
Keywords:
microRNA; diffuse large B-cell lymphoma; biomarkers
